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Abstract Clinical staging model at the nanoscale (CSMN) has
been performed on adenocarcinoma of the colon from five
patients ranging in age from 57 to 76 years based on determining
their malignant size, estimating their doubling time through
imaging techniques, and thus by measuring the average of the
tumor nanoparticle doubling time their histologic grade has been
identified at the nanoscale. Another two pathologic staging
models at the nanoscale PSM [H-3] N and PSM [C-14] N for
evaluating the histologic grade have been performed on those
tumors based on the in vitro measuring of cell proliferating of
tumor slices by either of the [H-3] tritiated and [C-14]
thymidine incorporation hypothesizing in PSM [H-3] N that
the malignant fraction of the detected tumor is the unlabeled
fraction of the tumor by the [H-3] tritiated thymidine, while
positing in PSM [C-14] N that the percentage increase of
the tumor nanoparticle doubling time than that of the normal
tissue at the Natural Background Radiation is equivalent to
the percentage deficit of [C-14] incorporation in tumor cells.
The consistency of results of the three staging models has
been analyzed using ANOVA. Identical histologic grades
have been identified by the three staging models for tumors
of early stages (p<0.0001). While for those of advanced
disease, evaluation of the histologic grade was identical by
CSMN and PSM [H-3] N only (p<0.0001), whereas was
invalid by PSM [C-14] N.
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1 Introduction
Staging of cancer is the main objective of cancer screening,
and considered the most important predictor of survival,
where cancer treatment is primarily determined by staging
which can be changed according to progression of the
disease. There are two types for cancer staging, clinical
and pathologic, where both are considered a supplement
for each other (Lucas 2006), each of them describes the
anatomic extent of the cancer at the time of diagnosis before
the application of definitive treatment to develop classifica-
tion into stages, which serves for treatment guidance and for
comparing with the end results of the applied treatment
(Wilson and Jungner 1968). Clinical stage is based on all
of the available information obtained before a surgery to
remove the tumor, while pathologic stage adds additional
information gained by examination of the tumor microscop-
ically after surgery expressing the stage before therapy only
(Lucas 2006). Usually, cancer staging by either type
expresses the extent that cancer has spread, and is usually
described by numbers I to IV with IV having more progres-
sion. Such classification, which is well known by the TNM
system, involves the tumor size (T) and the regional lymph
node involvement (N) and/or distant metastasis (M), is
based on the premise that cancers of the same histology
and anatomic sites share similar patterns of growth and
metastasis (AJCC 1998). Thereby, staging by those numbers
which reflect the histologic grade is considered very wide and
unspecified to describe the extent and aggressiveness of the
disease in patients, allowing to either of over or lower estima-
tion to the administered dose that contributes to risks of tumor
regrowth and metastasis (Moawad 2011). E. Moawad has
introduced a clinical staging by imaging techniques that allow
accurate cancer staging that helps to administer the appropri-
ate low-waste dose and modify it by monitoring an earlier
response to therapy which contributes besides developing
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dose-delivery skills to the success of all types of cancer treat-
ments (Moawad 2010, 2011). In the same time, it was possible
to correlate the in vitro data with patient response to therapy
and the incorporation of [3H] tritiated thymidine and the [14C]
thymidine by slices of their tumors (Baserga and Lisco 1963;
Wimber and Quastler 1963). No responses to therapy were
found in those patients whose tumors when incubated in vitro
with thymidine showed poor nucleoside incorporation. In
contrast, patients receiving benefit from cancer therapy were
those whose tumors when incubated in vitro with thymidine
showed good nucleoside incorporation (Wolberg and Brown
1962). Such great variability reflects their variability in growth
rate propensity for metastasis, or in other words, in their stages
and consequently their corresponding grades. Thus, patholog-
ical staging has been assessed on the basis of measurements of
the incorporation of [3H] tritiated thymidine and the [14C]
thymidine in vitro in the tumor slices. Current approach aims
to present clinical and pathological staging models of the
cancer at the nanoscale to obtain more accurate assessment
for the main factors of the prognostic determinants in the
classification for cancer staging.
Clinical staging model at the nanoscale (CSMN) E. Moa-
wad has presented a clinical model for cancer grading in
which the patient-specific histologic grade has been identi-
fied by evaluating the tumor energy (ETumor) based on
measuring tumor doubling time (tD) which expresses the
rate of growth by imaging techniques (Moawad 2010,
2011), and estimating the percentage of the hypoxic cells
(H%) which expresses the tumor histologic classification,
and inversely proportional to the total number of the malig-
nant cells of the tumor whose value is ranging between
8 and 20 % (Moawad 2010, 2011). Thus, the energy of the
hypoxic cell (EHypoxic.cell) which expresses the histologic
grade at the cellular level can be estimated from Emad
formula after measuring the tumor tD as follows:
EHypoxic:cell ¼ ln ln ln2tD
 2" #
Emad; ð1Þ
Emad ¼ 23; 234:59MeV: ð2Þ
Thus, provided that patient-specific histologic grade (ETumor)
is the summation of energies of all the tumor hypoxic cells
(ΣEHypoxic.cell) then:
ETumor ¼ ΣEHypoxic:cell ¼ M% Co  H%
 EHypoxic:cell
 23; 234:59 MeV; ð3Þ
where M% is the percentage of the tumor malignant fraction,
and C0 is the total number of tumor cells (Moawad 2010,
2011). Knowing that a tumor of 1 g converted into 109 ng
contains 109 cells, it would be more convenient to
express the tumor histologic grade by nanoscale as
equivalent to the average growth energy of a tumor of
1 ng or one nanoparticle (Eng) investigating whether we
can directly control matter on the molecular scale. Here-
by, in all sections of the current approach the tumor cell
will be expressed by the tumor nanoparticle, i.e., ECell0Eng.
Thus, from Eq. 3, it can be deduced that
Eng ¼ ETumor= M% Coð Þ ¼ H% EHypoxic:cell Emad ð4Þ
and consequently the average doubling time of the tumor
nanoparticle would be equivalent to:





Thus, from Emad formula the histologic grade of the tumor
nanoparticle would be:















Pathological staging model by [3H] tritiated thymidine at
the nanoscale Based on the in vitro measuring of cell prolif-
erating of tumor slices by [3H] tritiated thymidine incorpora-
tion, current approach introduces another pathological model
for cancer grading at the nanoscale (pathological stagingmodel
by [3H] tritiated thymidine at the nanoscale (PSM [3H] N)); as
labeling of cells by [3H] tritiated thymidine has been common-
ly used as an indicator of the proliferative capacity of tumor
cells (Lieb and Lisco 1966), conversely the unlabeled tumor
fraction (U%) has been hypothesized by this model as an
indicator for the inhibition to cell-proliferating rate. As inhibi-
tion to cell-proliferating rate accompanied by cell cycle arrest
distinguishes the malignant cells from the normal ones, then
the unlabeled tumor fraction (U%) can be considered the
malignant tumor fraction (M%) that previously presented as
one of the factors of the clinical staging shown in Eq. 3, i.e.,
U%0M%. Thus, such inhibition to cell-proliferating rate
can be monitored by the deficit of [3H] tritiated thymi-
dine incorporation in the tumor malignant cells, provid-
ed that energy of such deficit part (U%) of the
thymidine dose is equivalent to the energy of the ma-
lignant fraction (M%) of that tumor and denoted by
ETumor which expresses the patient-specific histologic
grade. Accordingly, by knowing the percentage of the
unlabeled cells (U%) of the tumor then:
ETumor ¼ U% ¼ M%ð Þ  E3H:Thymidine:Dose MeV ð7Þ
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on condition that U%<1. Consequently, the patient-specific
histologic grade at the nanoscale would be:
Eng ¼ ETumor= M% Coð Þ ¼ E3H:Thymidine:Dose=Co ð8Þ
Pathological staging model by [14C] thymidine at the
nanoscale It is well known that in all cancer stages from early
to advanced disease, cancer cells are known to have alterations
in multiple cellular signaling pathways drives normal cell to
carcinoma (Wu et al. 2009). One of the most important signals
is the continuous deficit in cell proliferation rate accompanied
by a progressive cell cycle arrest along those stages (Reiskin
and Mendelsohn 1964). Significant efforts have been made to
understand the kinetic analysis of cell proliferation that drives
cancer development and progression (Allard et al. 2004).
There is as yet little to distinguish the cancerous cell from a
variety of normal cells which have also been analyzed (Reis-
kin and Mendelsohn 1964) as basis of such efforts. Since
labeling of cells by [14C] thymidine is commonly used as well
in vitro in measuring cell proliferation rate, where the incor-
poration of the [14C] thymidine into the dividing cells and the
level of this incorporation is proportional to the amount of cell
proliferation (Reszka et al. 2001). Thus, the second patholog-
ical staging model presented by current thesis (pathological
stagingmodel by [14C] thymidine at the nanoscale (PSM [14C]
N)) posits that the inhibition to cell-proliferating rate due to all
the genetic variations and the aberrant activations accompa-
nied by cell cycle arrest that drive the normal cell to carcinoma
induces a deficit of [14C] thymidine incorporation in the
detected samples compared to the control one. Consequently,
percentage of the deficit of [14C] thymidine incorporation
(D%) in those samples compared to the control one is equiv-
alent to the increase of the tumor nanoparticle tD, i.e., tD.ng
compared also to the cell doubling time at the natural back-
ground radiation (tD.NBR) which is equal to 1.884220083 s
(AJCC 1998), i.e.
tD:ng ¼ 1þ D%ð Þ  tD:NBR; ð9Þ
on condition that D%<1. And thus PSM [14C] N is valid for
samples of nanoparticle doubling time less than twice that of
normal tissue nanoparticles at the NBR, i.e., tD.ng<2tD.NBR.
Accordingly, the histologic grade of the detected samples at
the nanoscale can be derived by Emad formula as follows:
Eng ¼ ln ln ln21þ D%ð Þ  tNBR
 2" #
 23; 234:59MeV ð10Þ
Since the identified histologic grade (Eng) by those mod-
els shown in Eqs. 6, 8, and 10 should be identical, and as
factors concerned in those models should confirm basis of
the main factors assessment of the prognostic determi-
nants in the classification for cancer staging by the
TNM system. The objective of the current approach is
to investigate the consistency of the results of those
models to provide a clear-cut criterion for accepting or
rejecting the hypotheses of those models.
2 Methods and materials
As conducted and described by Larry M. Lieb and Hermann
Lisco (1966), adenocarcinomas of the colon from five patients
ranging in age from 57 to 76 years were obtained immediately
following tumor resection in the operating room. The in vitro
uptake of [3H] tritiated thymidine by those tumors cells was
studied. The tumors were incubated for 1 h at 37.5±0.5 °C in a
beaker containing 100 ml of Ringer’s solution and 100 μCi of
[3H] tritiated thymidine (Schwarz Laboratories, Inc., Mt. Ver-
non, New York) with a specific activity of 3.0 Ci/mmole . The
tumor doubling time (tD) has been estimated, total numbers of
tumor cells (Co), and the percentages of labeled cells in each
tumor were measured for all five tumors. At the same time as
conducted and described by Reszka et al. (Reszka et al. 2001),
the corresponding in vitro uptake of [14C] thymidine by those
tumors cells was studied after incubation of 72 h, where the
amount of [14C] thymidine (NEN, Boston,MA) for measuring
cell proliferation rate for each sample was proportional to its
number of cells. The amount of [14C] thymidine that used for
measuring the largest tumor (25,838 cells) was 0.5 μCi, while
the amounts used for other tumors has been proportionally
decreased by ratio of their number of cells to that of the largest
one. Data and results as shown by Larry M. Lieb and Her-
mann Lisco, and the amount of the used [14C] thymidine for
each tumor according to its Co with respect to that of the
largest tumor along with its corresponding in vitro uptake
carried out by current approach are tabulated in Table 1 to
cover all data required for determining factors of the prognos-
tic determinants of the presented pathological and clinical
staging models; PSM [3H] N, clinical staging model at the
nanoscale (CSMN), and PSM [14C] N.
3 Results and analysis
The released energy of 100μCi of [3H] tritiated thymidine (half-
life time012.32 years, decay energy00.01859 MeV (Barbalace
1995a)) during the incubation of 1 h is equivalent to:
E3H:Thymidine:Dose ¼ 100 106  3:7 1010 
12:32 3:16 107
ln 2




While the released energy of 0.5 μCi of [14C] thymidine
that used for the largest tumor which is the first tumor (half-
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life time05,730 years, decay energy00.156 MeV (Barbalace
1995b)) during the incubation of 72 h is equivalent to:
E14C:Thymidine:Dose ¼ 0:5 106  3:7 1010
 5; 730 3:16 10
7
ln 2




Whereas, the amounts of the used [14C] thymidine for
other tumors would be decreased by a ratio of their number
of cells to number of cells of the largest tumor which is the
first one.
1st tumor: From Table 1 the percentage of labeled cells by
[3H] tritiated thymidine and number of cells
were 26.5 % and 25,838, respectively. Thus,
U% 0100 − 26 . 5 073 . 5 % , f r om Eq . 7
ETumor 1ð Þ ¼ 0:735 2:47617956 108 ¼ 1:81999198
108 MeV. Consequently, from Eq. 8 the his-
tologic grade (Eng) of first tumor according to
the PSM [3H] N would be 9,583.4 MeV, which
according to the CSMN through Eqs. 5 and 6
and by taking (U%0M%), corresponds to H%0
8.45 % and tD.ng02.369134131 s<2 tD.NBR.
While from Table 1, the amount of the used
[14C] thymidine was 0.5 μCi, and the percent-
age of labeled cells by [14C] thymidine was
75.67 %. Thus, D%0100−75.67024.33 %,
from Eq. 9 tD.ng01.2433 tD.NBR02.3426474 s
which is 99 % identical to what has been mea-
sured by CSMN. Consequently, from Eq. 10 the
histologic grade of the first tumor according to
the PSM [14C] N Eng would be 9,156.36 MeV
which is 96 % identical to what has been mea-
sured by PSM [3H] N.
2nd tumor: From Table 1 the percentage of labeled
cells by [3H] tritiated thymidine and num-
ber of cells were 20.2 % and 22,015, respec-
tively. Thus, U%0100−20.2079.8 %, from
Eq. 7 ETumorð2Þ ¼ 0:798 2:47617956 108
¼ 1:97599129 108MeV . Consequently,
from Eq. 8 the histologic grade (Eng) of second
tumor according to the PSM [3H] N would be
11,247.69 MeV, which according to the CSMN
through Eqs. 5 and 6 and by taking (U%0M%),
corresponds to H%09.8 % and tD.ng0
2.477723427 s<2 tD.NBR. While from Table 1,
the amount of the used [14C] thymidine was
0:5μCi 22;01525;838 , and the percentage of la-
beled cells by [14C] thymidine was 69 %.
Thus, D%0100−69031 %, from Eq. 9
tD.ng01.31 tD.NBR02.46837259 s which is
≈100 % identical to what has been mea-
sured by CSMN. Consequently, from
Eq. 10 the histologic grade of the second
tumor according to the PSM [14C] N Eng
would be 11,109.553 MeV which is ≈99 %
identical to what has been measured by
PSM [3H] N.
3rd tumor: From Table 1 the percentage of labeled cells by
[3H] tritiated thymidine and number of cells
were 10.9 % and 13,443, respectively. Thus,
U% 0100 − 10 . 9 089 . 1 %, f rom Eq . 7
ETumor 3ð Þ ¼ 0:891 2:47617956 108 ¼ 2:20627599
108 MeV. Consequently, from Eq. 8 the his-
tologic grade (Eng) of the third tumor according
to the PSM [3H] N would be 18,419.84 MeV,
which according to the CSMN through Eqs. 5
and 6 and by taking (U%0M%), corresponds to
H%015.73 % and tD.ng03.064650384 s<2
tD.NBR. While from Table 1, the amount of the
used [14C] thymidine was 0:5μCi 13;44325;838 , and
the percentage of labeled cells by [14C] thymi-
dine was 43.31 %. Thus, D%0100−43.310
56.69 %, from Eq. 9 tD.ng01.5669 tD.NBR0
2.952384449 s which is 96.34 % identical to
what has been measured by CSMN. Conse-
quently, from Eq. 10 the histologic grade of the
third tumor according to the PSM [14C] N Eng
would be 17,238.24 MeV which is 93.6 % iden-
tical to what has been measured by PSM [3H] N.
Table 1 Number of cells,
percent of labeled cells, and

















1 25,838 26.5 % 0:5μCi 75.67 % 22
2 22,015 20.2 % 0:5μCi 22;01525;838 69 % 28
3 13,443 10.9 % 0:5μCi 13;44325;838 43.31 % 48
4 9,800 4.5 % 0:5μCi 9;80025;838 16.65 % 112
5 9,605 15.4 % 0:5μCi 9;60525;838 24.67 % 35
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4th tumor: From Table 1 the percentage of labeled cells by
[3H] tritiated thymidine and number of cells
were 4.5 % and 9,800, respectively. Thus,
U% 01 00 − 4 . 5 095 . 5 % , f r om Eq . 7
ETumor 3ð Þ ¼ 0:891 2:47617956 108 ¼ 2:20627599
108 MeV. Consequently, from Eq. 8 the his-
tologic grade (Eng) of fourth tumor according to
the PSM [3H] N would be 25,267.14 MeV,
which according to the CSMN through Eqs. 5
and 6 and by taking (U%0M%), corresponds
to H%021.03 % and tD.ng03.880342339 s>2
tD.NBR. Accordingly, PSM [
14C] N is not valid
to evaluate the fourth tumor as tD.ng>2tD.NBR as
postulated in PSM [14C] N.
5th tumor: From Table 1 the percentage of labeled cells by
[3H] tritiated thymidine and number of cells
were15.4 % and 9,605, respectively. Thus,
U% 0100 − 15 .4 084 .6 % , f r om Eq . 7
ETumor 5ð Þ ¼ 0:846 2:47617956 108 ¼ 2:09484791
108MeV. Consequently, from Eq. 8 the his-
tologic grade (Eng) of the fifth tumor according
to the PSM [3H] N would be 25,780.11 MeV,
which according to the CSMN through Eqs. 5
and 6 and by taking (U%0M%), corresponds to
H%022.2356 % and tD.ng03.955245085 s>2
tD.NBR. Accordingly, PSM [
14C] N is not valid
to evaluate the fifth tumor as tD.ng>2 tD.NBR as
postulated in PSM [14C] N. But if such hypoth-
esis for PSM [14C] N validity has been ignored,
accuracy of PSM [14C] N would be decreased
with respect to the accuracy of each of PSM [3H]
N and CSMN as much as tD.ng increases more
than twice tD.NBR as follows: For the fourth tu-
mor, the amount of the used [14C] thymidine as
shown in Table 1 is 0:5μCi 9;80025;838 , and the
percentage of labeled cells by [14C] thymidine
was 16.65 %. Thus, D%0100−16.65083.35 %,
from Eq. 9 tD.ng01.8335 tD.NBR03.454652815 s
which is 89 % identical to what has been mea-
sured by CSMN. Consequently, from Eq. 10 the
histologic grade of fifth tumor according to the
PSM [14C] N Eng would be 22,021.41 MeV
which is 87.15 % identical to what has been
measured by PSM [3H] N. While for fifth tumor,
the amount of the used [14C] thymidine as shown
in Table 1 is 0:5μCi 9;60525;838 , and the percentage
of labeled cells by [14C] thymidine was 24.67 %.
Thus, D%0100−24.67075.33 %, from Eq. 9
tD.ng01.7533 tD.NBR03.303653538 s which is
93 % identical to what has been measured by
CSMN. Consequently, from Eq. 10 the histolog-
ic grade of fifth tumor according to the PSM
[14C] N Eng would be 20,710.1 MeV which is
80.33 % identical to what has been measured by
PSM [3H] N. The results of the physical analysis
to the in vitro uptake of tritiated thymidine by the
5 tumors are shown in table 2, where the consis-
tency of the results of the three staging models
has been analyzed using ANOVA (Table 2). The
relation of the derived values ofH% fromCSMN
which represents the histologic classification and
the measured values of Eng from PSM [
3H] N,
which represents the histologic grade at the cel-
lular level or at the nanoscale, shows perfect
direct correlation (r00.9999) between them for
all studied tumors as shown in Fig. 1. Thereby,
H% can be estimated by the following equation
model:
H ¼ 0:000821725Eng þ 0:57530248; ð11Þ
(R200.9998).
While Fig. 2 shows the strong inverse correlation be-
tween percentages of the hypoxic cells (H) and their
corresponding total number of tumor cells (C0) for the
studied tumors (r0−0.98) as postulated in the mathematical
model of the clinical staging, this indirect correlation
decreases dramatically (r0−0.36) as much as the tumor size
(C0) increases or decreases aggressively to confirm the
postulated range of the percentage of the hypoxic cells (H)
by the clinical model CSMN. At the same time, by knowing
tumor tD and the corresponding values of ETumor, Eng from
the pathological model PSM [3H] N, and then getting their
predicted value of (H) derived from Eq. 11, and then sub-
stituting all these values in Eqs. 1 and 3 of the clinical model
CSMN, the derived malignant tumor fraction (M%) would
be identical to the unlabeled tumor fraction (U%) for all
tumors as shown in Fig. 3 to confirm the hypothesis of PSM
[3H] N about their equivalence (M%0U% (p<0.0001)).
Therefore, it can be easily concluded that the unlabeled
fraction of tumor cells by the [3H] tritiated thymidine















































% of Hypoxic cells
Fig. 1 Percent of the hypoxic cells vs. average energy of the tumor
nanoparticle
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(U%) expresses the factor of the histologic classification in
cancer staging and grading. By measuring the factor of cell
proliferation rate in CSMN which is tumor tD, the relation of
the derived values of EHypoxic.cell from Eq. 1 and the mea-
sured values of W from PSM [3H] N shows perfect direct
correlation (r00.99) between them for all studied tumors as
shown in Fig. 4. Thus, depending on the clinical model
CSMN only, tumor evaluation can be performed by estimat-
ing M% and H% as follows:
M ¼ 79:53EHypoxic:cell  313:94; EHypoxic:cell
 5:2 Emad R2 ¼ 0:98 ;while M
¼ 100 for EHypoxic:cell  5:2 Emad ð12Þ
as previously shown by E. Moawad (2010, 2011). And
conversely by measuring the factor of histologic classifica-
tion in PSM [3H] N which is U, the factor of the histologic
grade of the hypoxic cell in CSMN which is EHypoxic.cell can
be estimated by the following equation model:
EHypoxic:cell ¼ 4:006403281
þ 0:011876884ðUÞEmad R2 ¼ 0:98 ;U < 100;
ð13Þ
while this equation is not valid for U<100. Whereas, from
Eqs. 3, 4, and 11, it can be deduced the strong direct
correlation (r00.9999) as well between H% and their
corresponding ( EHypoxic:cell MeVð ÞM%C0 ) as shown in Fig. 5, then
H% can be estimated by the following equation model:




(R200.99), when 5:994940269 < EHypoxic:cell MeVð ÞM%C0
 
< 14:
26815527, while for less values than the lower limit of this
interval, which represents validity of CSMN, the best esti-
mate of H% is 10 % as previously estimated in prior studies
(AJCC 1998; Baserga and Lisco 1963). Accuracy of PSM
[14C] N in evaluating the tumors of the earlier stages of
lower percentage of hypoxic cells as illustrated in the first
three cases shown in Fig. 6 confirms the hypothesis of PSM
[14C] N for the equivalence of the percentage of the deficit
part of [14C] thymidine incorporation (D%) in tumor of
earlier stage compared to the control tissue and the percent-
age of the increase of the tumor nanoparticle doubling time
(tD.ng) at earlier stages than that of the normal counterpart at
the natural background radiation (tD.NBR) (tD.ng0(1+D%)×
tD.NBR) (p<0.0001). While such accuracy of PSM [
14C] N in




















% of Hypoxic cells
Fig. 2 Percent of the hypoxic cells vs. number of cells
Conformity between the malignant and the 












































% Unlabeled fraction of
tumor cells
Fig. 3 Conformity of the percent unlabeled fraction of tumor by
tritiated thymidine and the malignant fraction in each tumor
% Malignant (Unlabeled) fraction of tumor cells 
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of tumor cells U %
Fig. 4 Percent of unlabeled (malignant) fraction of tumor cells U% vs.
energy of the hypoxic cell EHypoxic:cell
























% of Hypoxic cells
Fig. 5 Percent of the hypoxic cells vs. [EH (MeV)/(M%×C0)]
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evaluating the tumors of advanced disease (higher percent-
age of hypoxic cells) is less than that of the earlier stages as
illustrated in the last two cases shown in Fig. 6 which is
consistent with its validity condition (D%<1 or tD.ng<2
tD.NBR). Thereby, it can be easily concluded that the fraction
of the deficit part of [14C] thymidine incorporation (D%) in
tumor compared to the control tissue at the NBR expresses
the factor of the cell proliferation rate in cancer staging and
grading. The identical evaluation of the histologic grades for
the first three detected tumors of relatively earlier stages by
the PSM [3H] N, CSMN, and PSM [14C] N (p<0.0001)
boost the confidence to accept the hypotheses of those
models and to comply with the basis of the main factors
assessment of the prognostic determinants in the classifica-
tion for cancer staging by the TNM system.
4 Discussion
Although, variations in tumor response to cancer therapies
have been observed frequently by clinicians in patients of
tumors have been identified by same stage and degree, so
that those tumors appeared identical by all gross and histo-
logical parameters according to the TNM system. In some,
the tumors may respond effectively, whereas in the others
the tumors are unaffected by the drug and rapidly dissemi-
nate and kill them (Wolberg and Brown 1962). Such varia-
tions have led latter to believe that dosimetry never inherits
identical results! (Matthay KK 2001). Recently, E. Moawad
has attributed such random variations to the wide and insuf-
ficient staging by the TNM system that leads to dose assess-
ment using standard models and consequently to a wide
range of doses, responsible for tumor regrowth and second
cancer risks (Moawad 2010, 2011). And emphasized that
tumor growth rate is a major factor should be considered in
cancer staging to target a patient-specific histologic grade
and consequently a patient-specific appropriate dose
(Moawad 2010, 2011). Thus, patient-specific histologic
grade is the main objective of the advanced cancer
staging and considered the most important predictor of
survival, where cancer treatment is primarily determined
according to it. As cancer staging by either of the clin-
ical or pathological type should conform to each other to
strengthen the confidence to both types, then basis for
staging by either type should be assessed on identifying
the factors of the prognostic determinants for the histo-
logic classification and the anatomic extent of the cancer
that lead to identical histologic grade identified by either
type for the same tumor. According to the TNM system,
the factors of the staging that should be considered focus
on tumor location, size, rate of growth, histologic classi-
fication, and the anatomic extent which the disease has
spread (AJCC 1998). Those different factors measured by
both types of staging should be linked together such that
from clinical measurements, the pathologic ones can be
predicted and vice versa. The goal of this study is to
present models of clinical and pathological staging of the
cancer at the nanoscale parallel and comply with what is
applied and achieved in the staging by the TNM system.
Recently, rate of cell proliferation has been expressed
using Emad formula by cell growth energy (CGE) which
is the amount of energy of all cellular kinetics including
all the aberrant genetic variations that drive normal cell
to cancer (Moawad 2010, 2011). Thus, the progress
through measuring cellular kinetics allowed the improve-
ment of the factors of the clinical model CSMN as
(EHypoxic.cell, tDng, and Eng) to distinguish the normal
tissue from the cancerous one which must be given
prime consideration in evaluating and comparing different
therapeutic regimens. For the pathological models PSM
[3H] N and PSM [14C] N, [3H] tritiated thymidine and
[14C] thymidine are commonly used in vitro in cell
proliferation assays, where both are incorporated into
dividing cells and the level of this incorporation, mea-
sured using a liquid scintillation counter, is proportional
to the amount of cell proliferation (Reszka et al. 2001). It
was possible to correlate the in vitro data with patient
response to therapy and the incorporation of [14C] thy-
midine and [3H] tritiated thymidine by slices of their
tumors. No responses to therapy were found in those
patients whose tumors when incubated in vitro with
either of them showed poor nucleoside incorporation. In
Nanoparticle doubling time according to the 




































Fig. 6 Identical results of
CSMN, PSM [H-3] N, and
PSM [C-14] N in evaluating
tumors of earlier stages, while
those of advanced stages
CSMN, PSM [H-3] N are more
efficient
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contrast, patients receiving benefit from cancer therapy
were those whose tumors when incubated in vitro with
either of them showed good nucleoside incorporation
(Wolberg and Brown 1962). The latter have attributed
the considerable variation in the percentage of labeled
cells by either of [14C] and [3H] tritiated thymidine that
indicates cell proliferating for similar histological cancer-
ous tissues to errors in the technique. While such great
variability have been attributed by those presented mod-
els to tumors variability in growth rate (tD) propensity for
metastasis, or in other words, to the specific patient
stages and consequently their corresponding grades. The
anatomic extent to which the disease has spread is no
longer the most important factor determining prognosis.
The added factors considered in the clinical model
CSMN are (1) the tumor doubling time (tD) which
expresses the cell proliferative rate of the hypoxic cell
and is considered an indicator for the amount of inhibi-
tion to cell growth. The longer the tD of the tumor the
more tumor hypoxic cell cycle arrest accompanied by
aberrant genetic variations drive normal cell to carcino-
ma. Energy drives those aberrant genetic variations in the
hypoxic cell (EHypoxic.cell) can be estimated using Emad
formula by knowing the tumor tD as shown in Eq. 1.
While (ΣEHypoxic.cell) constitutes nearly the entire energy
of the malignant tumor fraction (ETumor) which consid-
ered the specific tumor histologic grade (Moawad 2010,
2011). (2) Consequently, percentage of the hypoxic cell
(H%) which represents the histologic classification should
be considered in cancer staging. The consistent results of
the perfect correlat ion between H% and their
corresponding averages of energy of the tumor nanopar-
ticle (Eng) revealed that accurate histologic diagnosis is
essential element in the specific evaluation of the tumor
to confirm the basis of the main factors assessment of
the prognostic determinants in the classification for can-
cer staging by the TNM system. In addition, the signif-
icant effect of H% on identifying the specific histologic
grade is consistent with what has been noted by others
that the extent of labeling of tumor cells by [3H] tritiated
thymidine in an in vitro system is dependent upon the
oxygen concentration, the type and number of cells com-
posing the tissue, and any fissuring or cracking of the
tissue which might allow deeper penetration of the incu-
bation fluid (Johnson and Bond 1961). Such note reveals
the role of hypoxic cells in inhibition to cell labeling
(i.e., to increase U% which expresses the increase of M%
as well) by thymidine incorporation as it is believed that
cell hypoxia contributes significantly to treatment failure
because cells in the hypoxic zones resist traditional
chemical disinfection. This happens for at least two rea-
sons: First, most agents cannot penetrate beyond 50–
100 μm from capillaries (Minchinton and Tannock
2006), therefore never reaching the cells in the hypoxic
regions. Second, the lower nutrient and oxygen supply to cells
in the hypoxic zones causes them to divide more slowly, i.e.,
longer cell tD than their well-oxygenated counterparts. There-
fore and in agreement with Emad formula shown in Eq. 1, the
hypoxic cells due to its higher CGE exhibit greater resistance
to chemical treatments, radiation, and thus serve to inhibit
thymidine incorporation that targets rapidly dividing cells or
requires oxygen for efficacy (Gillies and Gatenby 2007; Sul-
livan and Graham 2007; Brown 1999; Castello and David
2006). (3) The malignant tumor fraction (M%) which is a
dependent factor for cancer staging depends on the tumor tD
and consequently the EHypoxic.cell as shown in Table 1, thus it
was taken in consideration the values of EHypoxic.cell, and tD to
estimate M% as shown in Eq. 12. While the unique factor
concerned in the pathological model PSM [3H] N is the
unlabeled tumor fraction by the [3H] tritiated thymidine
(U%), which has been hypothesized to be equivalent to M%.
Perfect correlations between cancer staging factors of the
clinical model CSMN and the pathological one, PSM [3H] N
(EHypoxic.cell, U% and Eng, H%) confirms, provides a clear-cut
criterion for accepting the hypotheses of both models for
staging of cancer and strengthens the confidence as well in
the equivalence of the energy of the unlabeled fraction of the
tumor cells (U%) by the [3H] tritiated thymidine to that of the
malignant fraction (M%) of the detected tumor (U0M; p<
0.0001) as hypothesized by PSM [3H] N and shown in Fig. 3.
While the unique factor concerned in the pathological model
PSM [14C] N is the percentage of the deficit of [14C] thymi-
dine incorporation (D%) in the detected samples compared to
the control one at the NBR.D%was identical as hypothesized
by PSM [14C] N to the percentage average increase of tumor
nanoparticle doubling time than that of the normal tissue at
the NBR measured by either the clinical model CSMN
or the pathological one (PSM [3H] N; p<0.0001), which
provide as well a clear-cut criterion for accepting the hypoth-
esis of the pathological model (PSM [14C] N) for staging the
cancer. Also, the identical specific histologic grades at the
nanoscale (Eng) for the tumors of earlier stages evaluated by
CSMN, PSM [3H] N, and PSM [14C] N leaving no room for
Table 2 Results of the physical analysis to the in vitro uptake of
















Tumor (1) 73.5 9,583.40 4.9 8.45
Tumor (2) 79.8 11,247.69 4.95 9.8
Tumor (3) 89.1 18,419.84 5.04 15.73
Tumor (4) 95.5 25,267.14 5.17 21.03
Tumor (5) 84.6 25,780.11 4.99 22.356
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doubt to accept staging and grading of the earlier stages of
cancer by all those models. Validity of the pathological model
PSM [3H] N extends as long as tumor energy is lower than that
of the [3H] tritiated thymidine irrespective to their difference,
such condition is satisfied whenever U%<100 %. The more
such difference in favor of [3H] tritiated thymidine energy the
lower the proportion of the unlabeled tumor fraction, and
conversely the derived H% from Eq. 14 would be correspond-
ingly increased, thus consistency of the estimated histologic
grade by either PSM [3H] N or CSMN are not affected by the
increase in magnitude of energy of the [3H] tritiated thymidine
dose. While the validity of PSM [14C] N extends as long as the
detected tumor nanoparticle doubling time is less than twice
that of the normal nanoparticle at the NBR. Thereby, as PSM
[14C] N considers cell proliferation rate only, PSM [14C] N is
less efficient in evaluating tumors of advanced stages for their
higher cell proliferation rate inhibition, while CSMN and PSM
[3H] N are more efficient in evaluating the tumors of advanced
stages as those models consider the histologic classification as
previously shown in Section 3 besides the cell proliferation
rate. The main principal finding has emerged from this study
was the wide variation shown inM% and the wide variation in
the labeling index among the five cases so that Larry M. Lieb
and Hermann Lisco noted that “Our data provide no explana-
tion for such variations” (Lieb and Lisco 1966). The consistent
results of the current approach provide such explanation: as tD
varies among the five cases, their corresponding EHypoxic.cell
varies as well and consequently the unlabeled fraction of each
fraction (U%0M%) as shown in Eq. 12. Results of the current
approach are consistent with the results of models shown in
the previous studies taking into consideration that the value of
(M%) was 100 % in those prior studied cases as EHypoxic.cell
was greater than 5.2 Emad to satisfy the restriction of Eq. 12
(Moawad 2010, 2011). The classification by the TNM system
achieves reasonably precise description and recording of
the anatomic extent of cancer, it allows patients of differ-
ent histologic grades to be diagnosed by same stage, and
consequently receive same treatment, and therefore, it is
not surprising to find such random variations in responses
of those patients to their unspecified treatment. Thus, the
objective of those models which is the patient histologic
grade is a combination of the stage groupings of the T, N,
and M classifications in a specific-patient prognosis to
provide a simple way by which this information can
readily assist in choices of treatments and therapeutic
decisions, and thus those models will erase the blame
for non-matching results of the dosimetry.
5 Conclusion
CSMN, PSM [3H] N, and PSM [14C] N introduce innovative
solutions to improve identification of effective diagnostic tool
based on an individual’s unique tumor well-tolerated with
acceptably low rates of false positive and false negative results
to establish an efficient cancer screening by a reasonable
classification for staging of cancer. The anatomic extent to
which the disease has spread is no longer alone the most
important factor determining prognosis in the classification
for cancer staging. The tumor doubling time and the histologic
classification are the prognostic determinants to identify the
specific tumor histologic grade at the nanoscale which is the
most important variable that affects choices and allows physi-
cians to develop customized treatment plans for patients.
Models that consider each of cell proliferation rate and
the histologic classification as CSMN and PSM [3H] N are
more efficient than the ones that consider the cell prolifera-
tion rate only as PSM [14C] N in evaluating the histologic
grade of tumors of advanced stages.
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